In addition, similar to other pediatric blood cancers12–14, our present data revealed TP53 alterations as independent adverse markers associated with very poor prognosis in pediatric AML and suggested a refined stratification strategy to better identify high-risk patients for personalized medicine and outcome improvement. The gene discussed is TP53; the disease is acute myeloid leukemia.